Picture loading failed.

Anti-FCER2 therapeutic antibody (Pre-made Lumiliximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-327-1mg 1mg 3090
GMP-Bios-ab-327-10mg 10mg 21890
GMP-Bios-ab-327-100mg 100mg 148000
GMP-Bios-ab-327-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-FCER2 therapeutic antibody (Pre-made Lumiliximab biosimilar,Whole mAb)
INN Name Lumiliximab
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure3fzu:HL:CD
95-98% SI StructureNone
Year Proposed2004
Year Recommended2004
CompaniesBiogen Idec
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAllergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia
Development Techna